Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
| Revenue (TTM) | $104.97M |
| Gross Profit (TTM) | $-150.79M |
| EBITDA | $-205.90M |
| Operating Margin | -72.40% |
| Return on Equity | -29.10% |
| Return on Assets | -16.80% |
| Revenue/Share (TTM) | $1.40 |
| Book Value | $6.77 |
| Price-to-Book | 3.58 |
| Price-to-Sales (TTM) | 16.18 |
| EV/Revenue | 14.45 |
| EV/EBITDA | -17.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.50% |
| Shares Outstanding | $74.35M |
| Float | $54.25M |
| % Insiders | 1.22% |
| % Institutions | 114.54% |
Volatility is currently expanding
Xencor's antibody platform supports its in-house oncology and immunology pipeline. XNCR's settlement with Alexion helped improve its runway, which should be enough to reach obexelimab's FDA PDUFA decision. Obexelimab's FDA decision is for IgG4-related disease, although XNCR would capture royalties and milestones since it's a partnered asset.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xencor remains a Strong Buy, driven by pipeline progress in oncology and inflammatory disorders. XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients; pivotal study initiation is targeted for 2027. XmAb942, a next-gen anti-TL1A for ulcerative colitis, is differentiated by extended dosing and superior TL1A inhibition; interim phase 2b data are expected by the end of 2026.
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near term.
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XNCR and any ticker you trade — then tracks every position and per-strategy win rate.
